004720 — PharmGen Science Balance Sheet
0.000.00%
- KR₩76bn
- KR₩80bn
- KR₩171bn
Annual balance sheet for PharmGen Science, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 30,448 | 34,187 | 19,886 | 37,437 | 37,916 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 24,020 | 20,166 | 28,638 | 36,414 | 39,662 |
| Total Inventory | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 74,901 | 77,379 | 70,541 | 95,327 | 110,709 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 17,214 | 34,902 | 42,444 | 41,273 | 38,863 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 135,544 | 220,324 | 317,391 | 335,917 | 363,450 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 37,688 | 71,122 | 68,185 | 63,172 | 65,422 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 52,018 | 93,384 | 110,267 | 107,696 | 114,011 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Unrealized Gain / Loss | |||||
| Other Equity | |||||
| Total Equity | 83,526 | 126,940 | 207,125 | 228,221 | 249,439 |
| Total Liabilities & Shareholders' Equity | 135,544 | 220,324 | 317,391 | 335,917 | 363,450 |
| Total Common Shares Outstanding |